17 October 2024 The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents.
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold and open EU trade policy, according to a posting on the European Federation of Pharmaceutical Industries and Associations (EFPIA) website. 18 October 2024
After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). 18 October 2024
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
The safety of titanium dioxide as a food additive has been thrown into doubt, which itself has raised questions for drugmakers, reports PharmaLex's Thomas Eberwein. 12 August 2021
India’s Zydus Cadila, which has developed what will be India's second home-made vaccine against the coronavirus disease, has developed a live, attenuated recombinant measles virus-vectored vaccine, ZyCoV-MV, which is believed to provide long-term immunity from the infection. 12 August 2021
Central nervous system (CNS) specialist Axsome Therapeutics will hope a positive report from GlobalData could take the sting out of a recent run of bad news. 12 August 2021
Specialty UK pharma company Shield Therapeutics has entered into an exclusive licence agreement for Accrufer/Feraccru (ferric maltol) with Korea Pharma in the South Korea. 12 August 2021
Japanese drugmaker Chugai says it has launched Evrysdi (risdiplam) Dry Syrup 60mg for the treatment of spinal muscular atrophy (SMA). Evrysdi had been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) on June 23, 2021, and was listed on the national health insurance (NIH) reimbursement price list this week. 12 August 2021
The World Health Organization (WHO) has announced the next phase in its Solidarity trial: Solidarity PLUS will enroll hospitalized patients to test three new drugs in hospitalized COVID-19 patients. 12 August 2021
Eli Lilly has won a positive reimbursement decision in the UK for Verzenios (abemaciclib) as an option for people with advanced HR+ HER2-breast cancer. 12 August 2021
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in both non-dialysis dependent (NDD) and dialysis-dependent (DD) adult patients. 11 August 2021
Australia’s Therapeutic Goods Administration (TGA) granted provisional determination for Merck & Co’s molnupiravir, which will be processed by the US pharma major’s Merck Sharp & Dohme (Australia) Pty Ltd (MSD) unit. 11 August 2021
Japan’s Otsuka Pharmaceuticals has been handed a grant for up to $17.8 million from the Bill & Melinda Gates Foundation to support the clinical trial of a treatment-shortening regimen in drug-sensitive tuberculosis (TB). 11 August 2021
In the latest twist in the battle to acquire Vectura, the board of the UK inhaled therapies maker today acknowledged that Carlyle, one of the two bidders, has announced it will not improve its 155 pence per share offer for the company, as declared on August 6, through its Murano Bidco vehicle. 11 August 2021
Raman Sehgal, the founder of ramarketing, provides an Expert View on how pharmaceutical and life sciences businesses can market themselves in the post-pandemic environment. 10 August 2021
The Russian government is considering a further tightening of public procurements of drugs for state needs by introducing the “second extra” principle, when the application of a Russian company that failed to localize the production of raw materials within the country will be rejected, according to recent statements made by some senior state officials and some local media reports. 10 August 2021
A self-styled pioneer that promises to develop and deliver innovative medicines to patients at radically lower prices, is to raise up to $1.8 billion via a combination with special purpose acquisition company (SPAC) CM Life Sciences III, as it looks to accelerate its growth. 9 August 2021
The Indian subsidiary of Anglo-Swedish pharma major AstraZeneca has reported a 45.03% decline in its net profit to $1.37 million for the June ended fiscal quarter. 9 August 2021
Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). 9 August 2021
Following the announcement on Friday that the board of Vectura had accepted an improved takeover offer from private equity group Carlyle of 155 pence a share, Philip Morris has increased its previous offer for the UK inhaled medicines company. 9 August 2021
Through the Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz), Brazil’s Fiocruz has reached 80.4 million doses of the COVID-19 vaccine made available to the National Immunization Program (PNI), delivering around 2.2 million doses on July 30. 9 August 2021
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.